# A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

> **NCT00263666** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 100 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Rotarix
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Tritanrix-HB+Hib
- **BIOLOGICAL:** Polio Sabin

## Key facts

- **NCT ID:** NCT00263666
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-16
- **Primary completion:** 2008-02-07
- **Final completion:** 2008-02-13
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263666, "A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00263666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*